



WESTMINSTER
HEALTH FORUM

Biosimilars in the NHS - commissioning, development, and engagement with clinicians and patients 16th July 2019

CONDITIONS FOR USE OF TRANSCRIPTS:

This document is intended to provide a timely reference for interested parties who are unable to attend the event to which it refers. Some portions are based on transcripts of proceedings and others consist of text submitted by speakers or authors, and are clearly marked as such. As such, apart from where it is indicated that the text was supplied by the speaker, it has not been possible for the transcript to be checked by speakers and so this portion of the document does not represent a formal record of proceedings. Despite best endeavours by Westminster Forum Projects and its suppliers to ensure accuracy, text based on transcription may contain errors which could alter the intended meaning of any portion of the reported content. Anyone who intends to publicly use or refer to any text based on the transcript should make clear that speakers have not had the opportunity for any corrections, or check first with the speaker in question. If in doubt please contact the forum first.

Contents

<u>About this Publication</u>	3
<u>Agenda</u>	4
<u>Session Chair's opening remarks</u>	
Anne Marie Morris MP , Chair, All-Party Parliamentary Group on Access to Medicines and Medical Devices (<i>transcript</i>)	6
<u>Progress of biosimilar uptake in the NHS - cost, unwarranted variation and incentivising adoption</u>	
Suzy Heafield , Head of Medicines Value, NHS England and NHS Improvement (<i>transcript</i>)	7
Questions and comments from the floor (<i>transcript</i>)	11
<u>Priorities for development, competition and the impact of the Voluntary Scheme for Branded Medicines Pricing and Access</u>	
Alasdair Poore , Partner, Mills & Reeve (<i>transcript</i>)	15
Johnny Bane , Market Access Lead, Sandoz (<i>transcript</i>)	19
Karen Taylor , Research Director, UK Centre for Health Solutions, Deloitte (<i>transcript</i>)	22
Rodeina Challand , Director, Challand Biosimilar Consulting (<i>transcript</i>)	25
Professor Maya Buch , Professor of Rheumatology, University of Leeds; Honorary Consultant Rheumatologist, Leeds Teaching Hospitals NHS Trust and Director, NIHR BioResource Centre Leeds (<i>transcript</i>)	27
Questions and comments from the floor with Frances Sutcliffe , Technology Appraisal Committee Associate Director, NICE (<i>transcript</i>)	29
<u>Session Chair's closing remarks</u>	
Anne Marie Morris MP , Chair, All-Party Parliamentary Group on Access to Medicines and Medical Devices (<i>transcript</i>)	32
<u>Session Chair's opening remarks</u>	
Professor Maya Buch , Professor of Rheumatology, University of Leeds; Honorary Consultant Rheumatologist, Leeds Teaching Hospitals NHS Trust and Director, NIHR BioResource Centre Leeds (<i>transcript</i>)	33
<u>'Can biosimilars add value to the NHS? Yes, but...'</u>	
Dr Anant Jani , Honorary Research Fellow, Nuffield Department of Primary Care Health Sciences, University of Oxford (<i>transcript</i>)	34
<u>Next steps for the use of biosimilars - commissioning, engaging with clinicians and patient awareness</u>	
Sally Dickinson , Head of Information and Support Services, National Ankylosing Spondylitis Society (<i>transcript</i>)	37
Dr Shafie Kamaruddin , Deputy Medical Director and Consultant Physician in Diabetes and Endocrinology, County Durham and Darlington NHS Foundation Trust (<i>transcript</i>)	39
Evelien Moorkens , PhD Researcher, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven (<i>text submitted by speaker</i>)	41
James Roach , Programme Director, Integrated Care, NHS West Essex Clinical Commissioning Group (<i>transcript</i>)	43
Roderick Ball , Director, Impact Medical Education (<i>transcript</i>)	46
Questions and comments from the floor with Dr Anant Jani , Honorary Research Fellow, Nuffield Department of Primary Care Health Sciences, University of Oxford (<i>transcript</i>)	49
<u>The future for the regulation of biosimilars</u>	
Dr Christian Schneider , Director, National Institute for Biological Standards and Control (<i>transcript</i>)	58
Questions and comments from the floor (<i>transcript</i>)	63
<u>Session Chair's and Westminster Health Forum closing remarks</u>	
Professor Maya Buch , Professor of Rheumatology, University of Leeds; Honorary Consultant Rheumatologist, Leeds Teaching Hospitals NHS Trust and Director, NIHR BioResource Centre Leeds (<i>transcript</i>)	67
Stephanie Thomson , Forum Lead, Westminster Health Forum (<i>transcript</i>)	68
<u>List of Delegates Registered for Seminar</u>	69
<u>Contributor Biographies</u>	73
<u>About the Core Sponsors of the Westminster Health Forum</u>	76

Please be advised that speakers' PowerPoint presentations are included within the transcript itself, just beneath the relevant speaker's text. Please note that not all speakers are able to grant permission for us to include their slides.

About this Publication

This publication reflects proceedings at the Westminster Health Forum policy conference: Biosimilars in the NHS - commissioning, development, and engagement with clinicians and patients held on 16th July 2019. The views expressed in the articles are those of the named authors, not those of the Forum or the sponsors, apart from their own articles.

Although Westminster Health Forum is grateful to all sponsors for the funding on which we depend, participation in events and publications is never conditional on being a sponsor. As well as funding ongoing operations, sponsorship enables the Forum to distribute complimentary copies of publications, and offer complimentary tickets for events, to Government ministers, parliamentarians and officials most involved in policy.

This publication is copyright. Its copying, in whole or in part, is not permitted without the prior written consent of the publishers. However, extracts of the text may be reproduced for academic or review purposes, subject to the conditions of use outlined in the previous page, providing they are accurate, are not used in a misleading context and the author, their organisation and the Westminster Health Forum are acknowledged. We would also appreciate being informed.

Westminster Health Forum

UK Headquarters
4 Bracknell Beeches
Old Bracknell Lane West
Bracknell
Berkshire RG12 7BW

T: 01344 864796

F: 01344 420121

publications@westminsterforumprojects.co.uk

Directors

Peter van Gelder
Chris Whitehouse